137 related articles for article (PubMed ID: 36305127)
21. Quinazoline based 1,3,5-triazine derivatives as cancer inhibitors by impeding the phosphorylated RET tyrosine kinase pathway: Design, synthesis, docking, and QSAR study.
Pathak P; Naumovich V; Grishina M; Shukla PK; Verma A; Potemkin V
Arch Pharm (Weinheim); 2019 Sep; 352(9):e1900053. PubMed ID: 31380598
[TBL] [Abstract][Full Text] [Related]
22. Development of Novel Rhodanine Analogs as Anticancer Agents: Design, Synthesis, Evaluation and CoMSIA Study.
Krithika U; Prabitha P; Mandal SP; Yuvaraj S; Priya D; Wadhwani AD; Prashantha Kumar BR
Med Chem; 2021; 17(3):216-229. PubMed ID: 32520692
[TBL] [Abstract][Full Text] [Related]
23. Quinolidene-rhodanine conjugates: Facile synthesis and biological evaluation.
Subhedar DD; Shaikh MH; Shingate BB; Nawale L; Sarkar D; Khedkar VM; Kalam Khan FA; Sangshetti JN
Eur J Med Chem; 2017 Jan; 125():385-399. PubMed ID: 27688192
[TBL] [Abstract][Full Text] [Related]
24. Prediction of new Hsp90 inhibitors based on 3,4-isoxazolediamide scaffold using QSAR study, molecular docking and molecular dynamic simulation.
Abbasi M; Sadeghi-Aliabadi H; Amanlou M
Daru; 2017 Jun; 25(1):17. PubMed ID: 28666484
[TBL] [Abstract][Full Text] [Related]
25. Molecular Dynamics Guided Receptor Independent 4D QSAR Studies of Substituted Coumarins as Anticancer Agents.
Patil R; Sawant S
Curr Comput Aided Drug Des; 2015; 11(1):39-50. PubMed ID: 26081557
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological evaluation of purine-pyrazole hybrids incorporating thiazole, thiazolidinone or rhodanine moiety as 15-LOX inhibitors endowed with anticancer and antioxidant potential.
Afifi OS; Shaaban OG; Abd El Razik HA; Shams El-Dine SEA; Ashour FA; El-Tombary AA; Abu-Serie MM
Bioorg Chem; 2019 Jun; 87():821-837. PubMed ID: 30999135
[TBL] [Abstract][Full Text] [Related]
27. New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: Synthesis, CDK2 inhibition, QSAR and molecular docking studies.
Abd El-Karim SS; Syam YM; El Kerdawy AM; Abdelghany TM
Bioorg Chem; 2019 May; 86():80-96. PubMed ID: 30685646
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, biological evaluation, and molecular modeling studies of rhodanine derivatives as pancreatic lipase inhibitors.
Chauhan D; George G; Sridhar SNC; Bhatia R; Paul AT; Monga V
Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900029. PubMed ID: 31407389
[TBL] [Abstract][Full Text] [Related]
29. QSAR Evaluations to Unravel the Structural Features in Lysine-Specific Histone Demethylase 1A Inhibitors for Novel Anticancer Lead Development Supported by Molecular Docking, MD Simulation and MMGBSA.
Jawarkar RD; Bakal RL; Mukherjee N; Ghosh A; Zaki MEA; Al-Hussain SA; Al-Mutairi AA; Samad A; Gandhi A; Masand VH
Molecules; 2022 Jul; 27(15):. PubMed ID: 35897936
[TBL] [Abstract][Full Text] [Related]
30. 3D-QSAR and docking studies on ursolic acid derivatives for anticancer activity based on bladder cell line T24 targeting NF-kB pathway inhibition.
Yadav D; Nath Mishra B; Khan F
J Biomol Struct Dyn; 2019 Sep; 37(14):3822-3837. PubMed ID: 30261824
[TBL] [Abstract][Full Text] [Related]
31. Spectroscopic and In Silico DNA Binding Studies on the Interaction of Some New N-Substituted Rhodanines with Calf-thymus DNA: In Vitro Anticancer Activities.
Ali I; Lone MN; Alothman ZA; Badjah AY; Alanazi AG
Anticancer Agents Med Chem; 2019; 19(3):425-433. PubMed ID: 30277166
[TBL] [Abstract][Full Text] [Related]
32. Identification of potent aldose reductase inhibitors as antidiabetic (Anti-hyperglycemic) agents using QSAR based virtual Screening, molecular Docking, MD simulation and MMGBSA approaches.
Bakal RL; Jawarkar RD; Manwar JV; Jaiswal MS; Ghosh A; Gandhi A; Zaki MEA; Al-Hussain S; Samad A; Masand VH; Mukerjee N; Nasir Abbas Bukhari S; Sharma P; Lewaa I
Saudi Pharm J; 2022 Jun; 30(6):693-710. PubMed ID: 35812153
[TBL] [Abstract][Full Text] [Related]
33. Structure prediction, molecular simulations of RmlD from Mycobacterium tuberculosis, and interaction studies of Rhodanine derivatives for anti-tuberculosis activity.
N H; P SR; Sura M; Daddam JR
J Mol Model; 2021 Feb; 27(3):75. PubMed ID: 33547544
[TBL] [Abstract][Full Text] [Related]
34. New N-ribosides and N-mannosides of rhodanine derivatives with anticancer activity on leukemia cell line: Design, synthesis, DFT and molecular modelling studies.
Khodair AI; Awad MK; Gesson JP; Elshaier YAMM
Carbohydr Res; 2020 Jan; 487():107894. PubMed ID: 31865252
[TBL] [Abstract][Full Text] [Related]
35. Quantitative Structure-Activity Relationship Study of Camptothecin Derivatives as Anticancer Drugs Using Molecular Descriptors.
Ahmadinejad N; Shafiei F
Comb Chem High Throughput Screen; 2019; 22(6):387-399. PubMed ID: 31284856
[TBL] [Abstract][Full Text] [Related]
36. 2H-chromene derivatives bearing thiazolidine-2,4-dione, rhodanine or hydantoin moieties as potential anticancer agents.
Azizmohammadi M; Khoobi M; Ramazani A; Emami S; Zarrin A; Firuzi O; Miri R; Shafiee A
Eur J Med Chem; 2013 Jan; 59():15-22. PubMed ID: 23202485
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and evaluation of rhodanine derivatives as aldose reductase inhibitors.
Agrawal YP; Agrawal MY; Gupta AK
Chem Biol Drug Des; 2015 Feb; 85(2):172-80. PubMed ID: 24903533
[TBL] [Abstract][Full Text] [Related]
38. QSAR Modeling, Molecular Docking and Molecular Dynamics Simulations Studies of Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Anticancer Agents.
Abdizadeh R; Heidarian E; Hadizadeh F; Abdizadeh T
Anticancer Agents Med Chem; 2021; 21(8):987-1018. PubMed ID: 32698753
[TBL] [Abstract][Full Text] [Related]
39. Exploring the Gallic and Cinnamic Acids Chimeric Derivatives as Anticancer Agents over HeLa Cell Line: An in silico and in vitro Study.
Nolasco-Quintana NY; González-Maya L; Razo-Hernández RS; Alvarez L
Mol Inform; 2023 Jan; 42(1):e2200016. PubMed ID: 36065495
[TBL] [Abstract][Full Text] [Related]
40. Discovery of 1,3-diphenyl-1H-pyrazole derivatives containing rhodanine-3-alkanoic acid groups as potential PTP1B inhibitors.
Sun L; Wang P; Xu L; Gao L; Li J; Piao H
Bioorg Med Chem Lett; 2019 May; 29(10):1187-1193. PubMed ID: 30910462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
